Anti-Nociceptin receptor antibody (ab66219)

Overview

Properties

Associated products

Applications

Our Abpromise guarantee covers the use of ab66219 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF 1/100 - 1/400.
WB Use a concentration of 1 µg/ml. Detects a band of approximately 41 kDa (predicted molecular weight: 41 kDa).Can be blocked with Nociceptin receptor peptide (ab129205).
IHC-Fr 1/40 - 1/100.

Target

  • FunctionReceptor for the neuropeptide nociceptin/orphanin FQ. Has a potential role in modulating a number of brain functions, including instinctive behaviors and emotions. The activity of this receptor is mediated by G proteins which inhibits adenylyl cyclase.
  • Sequence similaritiesBelongs to the G-protein coupled receptor 1 family.
  • Cellular localizationCell membrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • H.sapiens mRNA for ORL1 receptor antibody
    • Kappa type 3 opioid receptor antibody
    • Kappa-type 3 opioid receptor antibody
    • kappa3-related opioid receptor antibody
    • KOR 3 antibody
    • KOR-3 antibody
    • KOR3 antibody
    • LC132 receptor like antibody
    • LC132 receptor, rat, homolog of antibody
    • MGC34578 antibody
    • Nociceptin receptor antibody
    • Nociceptin/orphanin FQ (N/OFQ) peptide receptor antibody
    • NOCIR antibody
    • NOP antibody
    • OOR antibody
    • Opiate receptor like 1 antibody
    • Opiod receptor like 1 antibody
    • Oprl1 antibody
    • OPRX_HUMAN antibody
    • ORL1 antibody
    • Orphanin FQ receptor antibody
    see all

Anti-Nociceptin receptor antibody images

  • Ab66219 staining of Oprl1 in rat brain (singulate cortex) by immunocytochemistry.

  • Developed using the ECL technique

    Performed under reducing conditions.

    Predicted band size : 41 kDa

    Sk-N-SH cells were incubated at 37°C for 24h with vehicle control (0 µM) and 1 µM of kainic acid (ab120100). Decrease expression of nociceptin receptor in SK-N-SH cells correlates with an increase in kainic acid concentration, as described in literature.

    Whole cell lysates were prepared with RIPA buffer (containing protease inhibitors and sodium orthovanadate), 30µg of each were loaded on the gel and the WB was run under reducing conditions. After transfer the membrane was blocked for an hour using 5% BSA before being incubated with ab66219 at 1 µg/ml and ab8227 at 1 µg/ml overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP (ab97051) at 1/10000 dilution and visualised using ECL development solution.

References for Anti-Nociceptin receptor antibody (ab66219)

ab66219 has not yet been referenced specifically in any publications.

Product Wall

Application Western blot
Loading amount 30 µg
Gel Running Conditions Reduced Denaturing (4-12)
Sample Human Cell lysate - whole cell (retinal pigment epithelium, fibroblasts, neuronal,)
Specification retinal pigment epithelium, fibroblasts, neuronal,
Blocking step BSA as blocking agent for 2 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
Username

Abcam user community

Verified customer

Submitted Nov 04 2013

Thank you for your clarification.

I can confirm the concentration of ab66219 (Batch: GR9812) of this ab is 1 mg/ml. The other antibody ab36204 (Lot: GR42382) is not affinity purified but whole antiserum so the IgG is not quantified. However, ...

Read More

Thank you for your enquiry and your interest in our products.

This is to confirm that we can only provide the concentration for affinity purified antibodies. For whole serum or supernatant we do not quantify the IgG concentration. I have cont...

Read More

Thank you again for contacting us, and I apologize for the extended delay regarding these peptides.

The blocking peptide for ab66219 is now available in our catalog as ab129205-

http://www.abcam.com/Oprl1-peptide-ab129205.html
...

Read More

Thank you for contacting us last week and for your patience while I have been working onadding these blocking peptides to our catalog. I apologize for the extended delay getting back to you.

Thesepeptides will be added to our catalog shortly,...

Read More

My colleague Teresa has forwarded your request to our team.

I have checked the datasheets for the PFA- perfusion fixed frozen section application (IHC-FoFr), andthe antibodiesare all not tested for this. This means unfortunately, that we cann...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"